Skip to main content
← Science / Explained

SERIES: MYTHS READ AGAINST THE SCIENCE

Human data show no clear thyroid-cancer signal, but the boxed warning stays

The Rat Finding

Semaglutide labels describe thyroid C-cell tumors in rodent studies. Tirzepatide labels describe thyroid C-cell tumors in rats.

Whether that finding translates to humans hasn't been established the same way. The boxed warning still applies to the label.

The Contraindication

The approved product labels contraindicate use in patients with a personal or family history of medullary thyroid carcinoma (a specific kind of thyroid cancer), or with Multiple Endocrine Neoplasia syndrome type 2 (a genetic condition).

Large human studies are broadly reassuring over short-to-moderate follow-up, but labels still treat the rodent C-cell finding as unresolved in humans.

What this means

References1 sources

How to read these sources

This article uses primary sources and reviews to separate mechanism, human evidence, and context.

Official LabelRegulator documents
Show 4 more source types
Human TrialStudies in people
ReviewExpert synthesis
MechanismCell and pathway logic
Public UpdateNews or announcements
  1. Official Label

    FDA-approved prescribing information (Wegovy)

    U.S. Food and Drug Administration / Novo Nordisk

    Novo Nordisk · 2026 WEGOVY (semaglutide) prescribing information: Boxed Warning and 5.1 Risk of Thyroid C-Cell Tumors Read source

    Used Here For

    Grounding the thyroid-cancer question in the approved label's boxed warning on thyroid C-cell tumors.

    Good For

    The FDA-approved facts behind the boxed warning, which rests on rodent findings whose relevance to humans has not been established.

    Not For

    Concluding the drug causes thyroid cancer in humans; the warning rests on rodent findings whose relevance to humans has not been established, and it still applies.

    FDA-approved labeling, DailyMed (National Library of Medicine), updated June 18, 2026